Chronic DLL4 blockade induces vascular neoplasms
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Delta-like 4 (DLL4)-mediated Notch signalling has emerged as an attractive target for cancer therapy. However, the potential side effects of blocking this pathway remain uncertain. Here we show that chronic DLL4 blockade causes pathological activation of endothelial cells, disrupts normal organ homeostasis and induces vascular tumours, raising important safety concerns.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [141]
Citations
Cites
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Self-citationHsieh, S. H., Ying, N. W., Wu, M. H., Chiang, W. F., Hsu, C. L., Wong, T. Y., Jin, Y. T., Hong, T. M., & Chen, Y. L. (2008) · Oncogene · doi:10.1038/sj.onc.1211029 · Cited by 229
Schmidt, M., Paes, K., De Mazière, A., Smyczek, T., Yang, S., Gray, A., French, D., Kasman, I., Klumperman, J., Rice, D. S., et al. (2007) · Development · doi:10.1242/dev.002576 · Cited by 183
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Li, J., & Harris, A. L. (2009) · Frontiers in bioscience · doi:10.2741/3438 · Cited by 141
Promoting angiogenesis to a fault
Hicklin, D. J. (2007) · Nature Biotechnology · doi:10.1038/nbt0307-300 · Cited by 13
Different roads to inactivation
Seton-Rogers, S. E. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2719 · Cited by 8
Flintoft, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2081 · Cited by 1
Cited by
Items 101–200 of 280
Targeting Notch to overcome radiation resistance
Yahyanejad, S., Theys, J., & Vooijs, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6714 · Cited by 79
“In animals, the long-term use of these antibodies, however caused marked histopathological changes in liver endothelial cells and induced vascular tumors [152].”
BackgroundTargeting cancer stem cells by using the nanoparticles
An, S. S. A., Jang, G.-B., Lee, H., Hong, I., & Nam, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s88310 · Cited by 74
“Despite the inhibition of Notch signaling can be achieved by γ-secretase inhibitors, inhibitory peptides,(105) and antibodies.(106) Clinical application of these inhibitory agents are currently restricted by their considerable side effects.”
Role of Notch in endothelial biology
Fernández-Chacón, M., García-Gónzalez, I., Mühleder, S., & Benedito, R. (2021) · Angiogenesis · doi:10.1007/s10456-021-09793-7 · Cited by 73
Li, J., Han, Y., Li, M., & Nie, C. (2019) · Cellular Reprogramming · doi:10.1089/cell.2018.0027 · Cited by 63
“DAPT is a c -secretase inhibitor and inhibits the presenilin - c -secretase complex and efficiently inhibits the Notch activity (Wu et al., 2010; Yan et al., 2010).”
Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions
Pedrosa, A., Trindade, A., Carvalho, C., Lentilhas-Graça, J., Carvalho, S., Peleteiro, M. C., Adams, R. H., & Duarte, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4380 · Cited by 67
“However, long-term blockade of Dll4 was found to lead to the development of vascular neoplasms [43] and other toxicities [44].”
BackgroundRoles of Notch Signaling in the Tumor Microenvironment
D’Assoro, A. B., Leon-Ferre, R. A., Braune, E.-B., & Lendahl, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116241 · Cited by 65
Developmental pathways in breast cancer and breast tumor-initiating cells: Therapeutic implications
Izrailit, J., & Reedijk, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.028 · Cited by 65
Notch Regulation of Tumor Angiogenesis
Bridges, E., Oon, C. E., & Harris, A. L. (2011) · Future Oncology · doi:10.2217/fon.11.20 · Cited by 65
“However, the clinical effectiveness of the gsecretase inhibitor is limited by significant toxic side effects [76,205].”
BackgroundRostama, B., Turner, J. E., Seavey, G. T., Norton, C. R., Gridley, T., Vary, C., & Liaw, L. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306541 · Cited by 67
Biktasova, A. K., Dudimah, D. F., Uzhachenko, R. V., Park, K., Akhter, A., Arasada, R. R., Evans, J. V., Novitskiy, S. V., Tchekneva, E. E., Carbone, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1154 · Cited by 59
“Multiple studies in recent years have called into question the use of Notch inhibitors to treat cancer because of an increased risk of endothelial cell tumors seen in animal models (48).”
BackgroundEndothelial notch signaling is essential to prevent hepatic vascular malformations in mice
Cuervo, H., Nielsen, C. M., Simonetto, D. A., Ferrell, L., Shah, V. H., & Wang, R. A. (2016) · Hepatology · doi:10.1002/hep.28713 · Cited by 59
“ENDOTHELIAL Notch SIGNALING REGULATES SINUSOID DIAMETER AND PREVENTS PORTO-SYSTEMIC SHUNTING Loss of Notch signaling in ECs leads to dilated sinusoids, originating around the central vein area, that ultimately form direct shunts between the portal and central veins and result in the development of HVMs. Increased live…”
BackgroundInfluentialNotch Suppresses Angiogenesis and Progression of Hepatic Metastases
Banerjee, D., Hernandez, S. L., Garcia, A. J., Kangsamaksin, T., Sbiroli, E., Andrews, J. P., Forrester, L. A., Wei, N., Kadenhe‐Chiweshe, A. V., Shawber, C. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1493 · Cited by 63
“DLL4 inhibition in animal studies can cause aberrant activation of endothelial cells (ECs), leading to formation of vascular tumors (16).”
BackgroundAre Cancer Stem Cells Radioresistant?
Hittelman, W. N., Liao, Y., Wang, L., & Milas, L. (2010) · Future Oncology · doi:10.2217/fon.10.121 · Cited by 65
ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis
Caolo, V., Swennen, G., Chalaris, A., Wagenaar, A., Verbruggen, S. E. L., Rose‐John, S., Molin, D. G. M., Vooijs, M., & Post, M. J. (2014) · Angiogenesis · doi:10.1007/s10456-014-9443-4 · Cited by 61
Notch Signaling in the Vasculature: Angiogenesis and Angiocrine Functions
Hasan, S. S., & Fischer, A. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041166 · Cited by 61
Miles, K. M., Seshadri, M., Ciamporcero, E. S., Adelaiye-Ogala, R. M., Gillard, B. M., Sotomayor, P. C., Attwood, K. M., Shen, L., Conroy, D., Kuhnert, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112371 · Cited by 59
“These findings are in agreement with a previous report on the effects of Dll4 blockade on rodent liver histology [14].”
ResultNotch Receptor-Ligand Engagement Maintains Hematopoietic Stem Cell Quiescence and Niche Retention
Wang, W., Yu, S., Zimmerman, G., Wang, Y., Myers, J., Yu, V. W. C., Huang, D., Huang, X., Shim, J., Huang, Y., et al. (2015) · Stem Cells · doi:10.1002/stem.2031 · Cited by 62
Self-citationNotch and Wnt signaling pathway in cancer: Crucial role and potential therapeutic targets (Review)
Xiao, Y., YONG, X., Tang, B., Qin, Y. W., ZHANG, J.-W., Zhang, D., Xie, R., & Yang, S. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3280 · Cited by 54
Chappell, J. C., Mouillesseaux, K. P., & Bautch, V. L. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301805 · Cited by 66
Qiao, L., Xie, L., Shi, K., Zhou, T.-F., Hua, Y., & Liu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051514 · Cited by 52
“In the mean time, Notch 1 and Notch 4 inhibit the proliferation, migration, and apoptosis of endothelial cells, maintain the ‘‘quiescence’’ phenotype of the cells, and keep vascular endothelium stable [64,65,66,67,68,69,70,71,72,73,74].”
Control of Blood Vessel Formation by Notch Signaling
Tetzlaff, F., & Fischer, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-89512-3_16 · Cited by 55
Targeting Notch Signaling for Cancer Therapeutic Intervention
Shao, H., Huang, Q., & Liu, Z. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00007-5 · Cited by 50
DLL1 orchestrates CD8 + T cells to induce long-term vascular normalization and tumor regression
Zhang, N., Yin, R., Zhou, P., Liu, X., Fan, P., Qian, L., Li, D., Zhang, C., Zheng, X., Deng, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020057118 · Cited by 62
Huang, C., Li, H., Xu, Y., Xu, C., Sun, H., Li, Z., Ge, Y., Wang, H., Zhao, T., Gao, S., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01478-5 · Cited by 54
RetractedHuang, Q. B., Ma, X., Zhang, X., Liu, S. W., Ai, Q., Shi, T. P., Zhang, Y., Gao, Y., Yang, F., Ni, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067294 · Cited by 52
“Many reliable studies have reported that the blockage of DLL4 leads to non-productive angiogenesis, [11,26] which implies that DLL4 inhibits angiogenesis.”
BackgroundProteases as activators for cytotoxic prodrugs in antitumor therapy.
Weidle, U. H., Tiefenthaler, G., & Georges, G. J. (2014) · PubMed · Cited by 48
Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
Harry, J. A., & Ormiston, M. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772305 · Cited by 52
Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer
Kuhnert, F., Chen, G., Coetzee, S., Thambi, N., Hickey, C., Shan, J., Kovalenko, P., Noguera‐Troise, I., Smith, E., Fairhurst, J. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3773 · Cited by 47
“Similar to what was reported, we found the vascular proliferation to be dose dependent and reversible upon cessationof treatment (35).”
BackgroundResultInfluentialTyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer
Shibuya, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392987 · Cited by 46
“reported that anti-Dll4 antibody treatment often induced a tumor, angioma, in mice, suggesting a risk in the host animals.(40) We found that double-deprivation stress with hypoxia and low nutrition, which mimics a condition under antiangiogenic therapy, induces a resistant phenotype in tumor cells.”
BackgroundNotch functions in developmental and tumour angiogenesis by diverse mechanisms1
Kangsamaksin, T., Tattersall, I., & Kitajewski, J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140233 · Cited by 48
Notch Signaling in Ocular Vasculature Development and Diseases
Dou, G., Wang, L., Wang, Y., & Han, H. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00256 · Cited by 46
The cautionary tale of side effects of chronic Notch1 inhibition
Ryeom, S. W. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45976 · Cited by 46
Zhdanovskaya, N., Firrincieli, M., Lazzari, S., Pace, E., Rossi, P. S., Felli, M. P., Talora, C., Screpanti, I., & Palermo, R. (2021) · Cancers · doi:10.3390/cancers13205106 · Cited by 47
Understanding the Role of Notch in Osteosarcoma
McManus, M. M., Weiss, K. R., & Hughes, D. P. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_4 · Cited by 51
Böcking, D., Wiltschka, O., Niinimäki, J., Shokry, H., Brenner, R. E., Lindén, M., & Sahlgren, C. (2013) · Nanoscale · doi:10.1039/c3nr04022d · Cited by 46
Hes1 suppresses acute myeloid leukemia development through FLT3 repression
Kato, T., Sakata‐Yanagimoto, M., Nishikii, H., Ueno, M., Miyake, Y., Yokoyama, Y., Asabe, Y., Kamada, Y., Muto, H., Obara, N., et al. (2014) · Leukemia · doi:10.1038/leu.2014.281 · Cited by 44
Induction of osteogenesis by bone-targeted Notch activation
Xu, C., Dinh, V. V., Kruse, K., Jeong, H.-W., Watson, E. C., Adams, S., Berkenfeld, F., Stehling, M., Rasouli, S. J., Fan, R., et al. (2022) · eLife · doi:10.7554/elife.60183 · Cited by 42
“While chronic Dll4 blockade was shown to cause sinusoidal vessel dilation in liver (Yan et al., 2010), histological analysis reveals no differences between pLIVEDll4(E12) and control livers (Figure 2B).”
BackgroundDing, X.-Y., Ding, J., Wu, K., Wen, W., Liu, C., Yan, H.-X., Chen, C., Wang, S., Tang, H., Gao, C.-K., et al. (2011) · Oncogene · doi:10.1038/onc.2011.467 · Cited by 43
“recently reported that persistent Dll4 blockage in ECs led to the occurrence of vascular neoplasm (Yan et al., 2010).”
BackgroundHajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations
CANALIS, E. M., & Zanotti, S. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0311-6 · Cited by 42
Unraveling the molecular and immunological landscape: Exploring signaling pathways in osteoporosis
Amroodi, M. N., Maghsoudloo, M., Amiri, S., Mokhtari, K., Mohseni, P., Pourmarjani, A., Jamali, B., Khosroshahi, E. M., Asadi, S., Tabrizian, P., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116954 · Cited by 43
Targeting embryonic signaling pathways in cancer therapy
Harris, P. J., Speranza, G., & Ullmann, C. D. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645808 · Cited by 42
“It is not, therefore surprising, that continuous dosing with Dll4 antibodies has been associated with treatmentemergent neovascular tuft formation and angiomas [78].”
BackgroundTherapeutic strategies against cancer stem cells in human colorectal cancer (Review)
Szaryńska, M., Olejniczak-Kęder, A., Kobiela, J., Spychalski, P., & Kmieć, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7261 · Cited by 49
“Chronic DLL4 blockade has been shown to activate endothelial cells, disrupt the homeostasis of organs (including the heart, lung, liver, and skin) and induce vascular tumors (114).”
BackgroundTHERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES
Roti, G., Sorrentino, C., & Cuneo, A. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.037 · Cited by 43
“dll4 showed to alter normal liver endothelial histology in mice, rats, and cynomolgus monkeys and promotes subcutaneous vascular neoplasms in rats.(46) Despite”
BackgroundSurface markers: An identity card of endothelial cells
Ribatti, D., Tamma, R., Ruggieri, S., Annese, T., & Crivellato, E. (2019) · Microcirculation · doi:10.1111/micc.12587 · Cited by 44
Therapeutic promise and challenges of targeting DLL4/NOTCH1
Yan, M. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-17 · Cited by 40
“While selective inhibition of DLL4 apparently avoids the gut toxicity that plagued the therapeutic application of GSIs, other safety concerns have been raised [27].”
InfluentialSelf-citationEndothelial cell malignancies: new insights from the laboratory and clinic
Wagner, M. J., Ravi, V., Menter, D. G., & Sood, A. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0013-2 · Cited by 41
“The observation of endothelial neoplasms forming after DLL4 inhibition in mouse models implicated Notch signaling in the development of proliferative vascular tumors, especially in the liver.(51) Conditional knockout of Notch1 in the liver in a mouse model resulted in hepatic angiosarcomas in 86% of mice by 50 weeks.”
BackgroundTrindade, A., Djokovic, D., Gigante, J., Badenes, M., Pedrosa, A., Fernandes, A.-C., Lopes-da-Costa, L., Krasnoperov, V. G., Liu, R., Gill, P. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029863 · Cited by 40
“A recent work [36] described that prolonged (over 8 weeks long) therapy with high dosages of Dll4 inhibitors (much higher than any of the dosages used in this work) can lead to low frequency non-lethal subcutaneous vascular neoplasms and histopathological changes in the liver.”
BackgroundFraser, H. M., Hastings, J. M., Allan, D. J., Morris, K. D., Rudge, J. S., & Wiegand, S. J. (2012) · Endocrinology · doi:10.1210/en.2011-1688 · Cited by 44
“In contrast, stringent, chronic inhibition of Dll4/Notch signaling with high-affinity antibodies (52) or gene deletions can lead to vascular abnormalities in some tissues (53, 54).”
An Antibody to Notch2 Reverses the Osteopenic Phenotype of Hajdu-Cheney Mutant Male Mice
CANALIS, E. M., Sanjay, A., Yu, J., & Zanotti, S. (2017) · Endocrinology · doi:10.1210/en.2016-1787 · Cited by 38
“events, and it may cause vascular tumors and gastrointestinal toxicity (60, 61).”
BackgroundThe Role of DLLs in Cancer: A Novel Therapeutic Target
Xiu, M., Liu, Y., & Kuang, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s244860 · Cited by 38
Kalén, M., Heikura, T., Karvinen, H., Nitzsche, A., Weber, H., Esser, N., Ylä‐Herttuala, S., & Hellström, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018709 · Cited by 41
“This effect is likely triggered in part by abnormal activation of liver endothelial cells as suggested by Yan et al and Wu et al [23,41].”
Haller, B. K., Bråve, A., Wallgard, E., Roswall, P., Sunkari, V. G., Mattson, U., Hallengärd, D., Catrina, S., Hellström, M., & Pietras, K. (2010) · Oncogene · doi:10.1038/onc.2010.176 · Cited by 38
Wittig, R., Rosenholm, J. M., von Haartman, E., Hemming, J. E., Genze, F., Bergman, L., Simmet, T., Lindén, M., & Sahlgren, C. (2013) · Nanomedicine · doi:10.2217/nnm.13.62 · Cited by 37
Tumor endothelial markers as a target in cancer
Ribatti, D., Ranieri, G., Basile, A., Azzariti, A., Paradiso, A., & Vacca, A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.725047 · Cited by 36
“Tumor endothelial cells differ from those of normal vessels for the expression of different cell surface markers, including two membrane-associated proteases, aminopeptidase A (APA), a constituent of activated pericytes in tumor angiogenesis [7] and functional target in angiogenic blood vessels [8], and aminopeptidase…”
BackgroundAnti-DLL4, a cancer therapeutic with multiple mechanisms of action
Gurney, A. L., & Hoey, T. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-18 · Cited by 36
Camelo, S., Raoul, W., Lavalette, S., Calippe, B., Cristofaro, B., Levy, O., Houssier, M., Sulpice, E., Jonet, L., Klein, C., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9290-0 · Cited by 34
“Recent evidence that chronic DLL4 inhibition induces vascular neoplasms [23] casts doubt on the safety of this approach.”
BackgroundCANALIS, E. M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.002 · Cited by 33
“Moreover, Notch neutralization is not without unwanted events, and it may cause vascular tumors and gastrointestinal toxicity [85,86].”
BackgroundCombined VEGFR and MAPK pathway inhibition in angiosarcoma
Wagner, M. J., Lyons, Y. A., Siedel, J., Dood, R. L., Nagaraja, A. S., Haemmerle, M., Mangala, L. S., Chanana, P., Lazar, A. J., Wang, W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88703-9 · Cited by 35
Notch-mediated cellular interactions between vascular cells
Cuervo, H., Mühleder, S., García-Gónzalez, I., & Benedito, R. (2023) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2023.102254 · Cited by 33
Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression
Shen, Z., Liu, Y., Dewidar, B., Hu, J., Park, O., Feng, T., Xu, C., Yu, C., Li, Q., Meyer, C., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.03.010 · Cited by 31
Wang, J., Liu, Q., Gao, H., Wan, D., Li, C., Li, Z., & Zhang, Y. (2017) · Tumor Biology · doi:10.1177/1010428317706203 · Cited by 31
An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice
Yu, J., Siebel, C. W., Schilling, L., & CANALIS, E. M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28960 · Cited by 31
“However, it is not known whether prolonged Notch3 neutralization results in unwanted events, as described for other Notch receptors (Ridgway et al., 2006; Yan et al., 2010).”
BackgroundAnti‐angiogenic therapy: Adapting strategies to overcome resistant tumors
Mitchell, D., & Bryan, B. A. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22764 · Cited by 32
“After 12 weeks of antiDLL4 treatment, liver pathology was evident, as was thymic atrophy and a dose-dependent increase in ulcerating, subcutaneous tumors in male rats with increased incidence of vascular neoplasms [Yan et al., 2010].”
BackgroundEmerging antibody combinations in oncology
Demarest, S. J., Hariharan, K., & Dong, J. (2011) · mAbs · doi:10.4161/mabs.3.4.16615 · Cited by 32
Therapeutic Targeting of Cancer Stem Cells
Maugeri‐Saccà, M., Zeuner, A., & Maria, R. D. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00010 · Cited by 35
“The promise Graham, R. A., Lum, B. L., Cheeti, S., Jin, J. Y., Jorga, K., Von Hoff, D. D., Rudin, C. M., Reddy, J. C., Low, J. A., and Lorusso, P. M. (2011). Pharmacokinetics of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glyco…”
BackgroundInfluentialAnti-angiogenic alternatives to VEGF blockade
Khan, K. A., & Bicknell, R. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9769-3 · Cited by 33
“Sustained treatment with anti-Dll4 antibodies result in abnormal liver pathology and can give rise to vascular neoplasms in various species including monkeys, rats and mice [59].”
BackgroundReduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension
Wang, S., Zhu, G., Jiang, D., Rhen, J. M., Li, X., Liu, H., Lyu, Y., Tsai, P., Rose, Y., Nguyen, T., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16065 · Cited by 32
Kałafut, J., Czerwonka, A., Anameriç, A., Przybyszewska-Podstawka, A., Misiorek, J. O., Rivero‐Müller, A., & Nees, M. (2021) · Cancers · doi:10.3390/cancers13246219 · Cited by 34
“However, it was shown that prolonged artificial inhibition of DLL4 causes pathological activation of endothelial cells, leading to impaired blood vessel morphology and histopathological changes in organs [340,341].”
BackgroundBlockade of Specific NOTCH Ligands: A New Promising Approach in Cancer Therapy
Briot, A., & Iruela‐Arispe, M. L. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1501 · Cited by 31
Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia
Taylor, J., Uhl, L., Moll, I., Hasan, S. S., Wiedmann, L., Morgenstern, J., Giaimo, B. D., Friedrich, T., Alsina‐Sanchís, E., Rigotti, F., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00622-y · Cited by 31
“However, in line with previous reports 45 , Notch inhibition had severe side effects, questioning the use of Notch-inhibiting drugs in humans at least when given over long time periods 25,52 .”
ResultTrindade, A., Djokovic, D., Gigante, J., Mendonça, L., & Duarte, A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3171-2 · Cited by 29
“Besides, chronic Dll4 blockade was found to disrupt normal organ vascular homeostasis and induce vascular tumor formation [15, 30, 31].”
Zhang, J., Qin, H., Wang, L., Liang, L., Zhao, X., Cai, W., Wei, Y., Wang, C., & Han, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.008 · Cited by 28
“, the formation of vascular neoplasms [27].”
BackgroundFormation of cardiovascular tubes in invertebrates and vertebrates
Strilić, B., Kučera, T., & Lammert, E. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0400-0 · Cited by 33
“However, although Dll4-mediated signaling has emerged as an attractive target for cancer therapy, chronic Dll4 blockade in mice and rats was shown to disrupt normal organ homeostasis and produced pathologies in multiple organs [ 124 ].”
BackgroundCzabanka, M., Brünner, J., Parmaksiz, G., Broggini, T., Topalovic, M., Bayerl, S., Auf, G., Kremenetskaia, I., Nieminen-Kelhä, M., Jabouille, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.019 · Cited by 26
“Downregulation of Dll4/Notch signalling has been shown to result in vascular neoplasms resulting from uncontrolled angiogenesis.(26) Moreover, Dll4 inhibition results in extensive angiogenesis overcoming the antiangiogenic effects of VEGFR2 – impairment.”
BackgroundOngoing Dll4‐Notch signaling is required for T‐cell homeostasis in the adult thymus
Billiard, F., Kirshner, J. R., Tait, M., DaNave, A., Taheri, S., Zhang, W., Waite, J. C., Olson, K., Chen, G., Coetzee, S., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041343 · Cited by 25
Combining Notch inhibition with current therapies for breast cancer treatment
Brennan, K. R., & Clarke, R. B. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012457437 · Cited by 27
“It is also worth noting that long-term treatment with Notch pathway inhibitors is associated with development of vascular tumours [Liu et al. 2011; Yan et al. 2010].”
BackgroundZhao, X., Dou, G., Wang, L., Liang, L., Tian, D., Cao, X., Qin, H., Wang, C., Zhang, P., & Han, H. (2013) · Neoplasia · doi:10.1593/neo.13550 · Cited by 27
“Because blocking Notch signaling leads to vascular neoplasms [25], activating Notch signaling might be an alternative choice.”
BackgroundQiu, X., Chen, L., Wang, C., Lin, Z., Chen, B., You, N., Chen, Y., & Wang, X. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.10.058 · Cited by 26
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Couch, J. A., Zhang, G., Beyer, J. C., de Zafra, C. L. Z., Gupta, P., Kamath, A. V., Lewin‐Koh, N., Tarrant, J. M., Allamneni, K. P., Cain, G. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1380 · Cited by 25
“Males were chosen for pilot evaluations based on the higher incidence of neoplastic lesions seen in males versus females following treatment with anti-DLL4 IgG1 (23).”
BackgroundMethodSelf-citationSelective Blockade of Transport via SERCA Inhibition: The Answer for Oncogenic Forms of Notch?
Ilagan, M. X. G., & Kopan, R. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.020 · Cited by 24
“Despite their ability to circumvent gut toxicity, sustained treatment with these reagents will likely cause vascular neoplasms, raising additional safety concerns (Yan et al., 2010).”
BackgroundVon Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch
Arreola, A., Payne, L. B., Julian, M. H., de Cubas, A. A., Daniels, A. B., Taylor, S., Zhao, H., Darden, J. A., Bautch, V. L., Rathmell, W. K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.92193 · Cited by 27
“Genetic loss of delta-like 4 (Dll4) or pharmacological blockade of Notch1 receptor signaling, such as through N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) treatment, leads to a hypersprouting phenotype and the formation of excessive vessel branches (10, 12), though this nascent vasculat…”
BackgroundOon, C. E., & Harris, A. L. (2011) · Biochemical Society Transactions · doi:10.1042/bst20110721 · Cited by 24
Reviews The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy?
Brzozowa-Zasada, M., Wojnicz, R., Kowalczyk-Ziomek, G. I., & Helewski, K. J. (2013) · Współczesna Onkologia · doi:10.5114/wo.2013.35588 · Cited by 29
“Why? Because similar changes were detected when Notch1 signaling was suppressed by γ-secretase or drugs targeting Notch1 receptors [40, 41].”
BackgroundInhibition of delta-like ligand 4 decreases Th1/Th17 response in a mouse model of multiple sclerosis
Eixarch, H., Mansilla, M. J., Costa, C., Kunkel, S. L., Montalbán, X., Godessart, N., & Espejo, C. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.038 · Cited by 26
Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature
Leach, A., Smyth, P., Ferguson, L., Steven, J., Greene, M. K., Branco, C. M., McCann, A. P., Porter, A. J., Barelle, C. J., & Scott, C. J. (2020) · Nanoscale · doi:10.1039/d0nr02962a · Cited by 24
Mao, H., Graziano, J. J., Chase, T. M. A., Bentley, C. A., Bazirgan, O. A., Reddy, N. P., Song, B. D., & Smider, V. V. (2010) · Nature Biotechnology · doi:10.1038/nbt.1694 · Cited by 26
“High-affinity antagonist antibodies targeting DLL4 are now in clinical trials, however, their safety has been questioned owing to hepatic toxicity with repeated us”
BackgroundTargeting DLL4 in Tumors Shows Preclinical Activity But Potentially Significant Toxicity
Li, J., Jubb, A. M., & Harris, A. L. (2010) · Future Oncology · doi:10.2217/fon.10.62 · Cited by 23
“investigated the potential side effects of blocking the DLL4-mediated Notch pathway in three animal species in nontumor-bearing animals [1].”
BackgroundInfluentialDjokovic, D., Trindade, A., Gigante, J., Pinho, M., Harris, A. L., & Duarte, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1605-2 · Cited by 20
“Moreover, therapeutic inhibition of Dll4 signaling may face important safety limitations since chronic Dll4/Notch impairment was found to destabilize normal endothelium giving origin to the formation of benign vascular tumors [12, 20, 21].”
BackgroundJakovljević, A., Nikolić, N., Čarkić, J., Andrić, M., Miletić, M., Beljić-Ivanović, K., Jovanovic, T. P., & Milašin, J. (2019) · Acta Odontologica Scandinavica · doi:10.1080/00016357.2019.1658896 · Cited by 21
“skin cancer, vascular tumours and hepatotoxicity) [53,54].”
Targeting γ-secretase in breast cancer
Han, J., & Shen (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s26437 · Cited by 27
“75,76 Of note, vision deterioration occurred in two out of 36 patients receiving semagacestat while none was reported in patients receiving placebo in the phase II clinical trial mentioned above, 70 although whether vision deterioration was due to abnormal angiogenesis in retina was not reported.”
Yan, X., Yang, Z., Chen, Y., Li, N., Wang, L., Dou, G., Liu, Y., Duan, J., Feng, L., Deng, S., et al. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4834-3 · Cited by 18
Kamath, A. V., Yip, V., Gupta, P., Boswell, C. A., Bumbaca, D., Haughney, P. C., Castro, J., Tsai, S. P., Pacheco, G., Ross, S., et al. (2014) · mAbs · doi:10.4161/mabs.36107 · Cited by 18
“Anti-DLL4 is a phage-derived humanized IgG1 monoclonal antibody that binds selectively to DLL4 from multiple species (mouse, rat, cynomolgus monkey, human) with high affinity.(17)”
BackgroundSelf-citationSharma, G., Jagtap, J. M. M., Parchur, A. K., Gogineni, V. R., Ran, S., Bergom, C. R., White, S. B., Flister, M. J., & Joshi, A. (2020) · Theranostics · doi:10.7150/thno.41171 · Cited by 15
“Despite successful results, clinical trials with DLL4-targeted antibodies and various preclinical studies with rats reported that intravenous injections of anti-DLL4 at 10 mg/kg every 3 days for a total of five doses results in pathological changes of liver and vascular neoplasms of skin, heart, and lungs [69].”
BackgroundBiological and clinical implications of cancer stem cells in primary brain tumors
Maugeri‐Saccà, M., Martino, S. D., & Maria, R. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00006 · Cited by 26
Growth factor signaling pathways in vascular development and disease
Grant, Z. L., & Coultas, L. (2019) · Growth Factors · doi:10.1080/08977194.2019.1635591 · Cited by 15
“Genes normally associated with EC growth and activation were upregulated in these lesions suggesting that DLL4/Notch maintains the quiescent phenotype, at least in these organs (Yan et al. 2010).”
BackgroundCancer Stem Cells: Are they Responsible for Treatment Failure?
Maugeri‐Saccà, M., Vici, P., Lauro, L. D., Barba, M., Amoreo, C. A., Gallo, E., Mottolese, M., & Maria, R. D. (2014) · Future Oncology · doi:10.2217/fon.14.126 · Cited by 14
Incongruence between transcriptional and vascular pathophysiological cell states
Fernández-Chacón, M., Mühleder, S., Regano, Á., García-Ortega, L., Rocha, S. F., Torroja, C., Sanchez-Muñoz, M. S., Lytvyn, M., Casquero-García, V., Andrés-Laguillo, M. D., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00272-4 · Cited by 16
“However, anti-Dll4 treatment was later shown to induce a loss of endothelial quiescence and vascular neoplasms, which were proposed to be the main cause of pathology in several organs 5,8,9 .”
BackgroundInfluentialGeneration of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model
Rothweiler, S., Dill, M. T., Terracciano, L., Makowska, Z., Quagliata, L., Hlushchuk, R., Djonov, V., Heim, M. H., & Semela, D. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.141 · Cited by 13
Dissection of Cardiovascular Development and Disease Pathways in Zebrafish
Chan, J. C.-Y., & Mably, J. D. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00004-2 · Cited by 14
Notch Pathway Modulators as Anticancer Chemotherapeutics
Sail, V., & Hadden, M. K. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00018-7 · Cited by 13
Metadata
- Authors
- Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D.
- Affiliations
- Genentech (US)
- Venue
- Nature
- Published
- 2010-02
- Volume
- 463
- Issue
- 7282
- Pages
- E6-E7
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030370645
- Cited by
- 280
- References
- 8
- Citations by year
- 2026: 3 · 2024: 3 · 2023: 12 · 2022: 5 · 2021: 17 · 2020: 9 · 2019: 10 · 2018: 17 · 2017: 17 · 2016: 11 · 2015: 27 · 2014: 26 · 2013: 36 · 2012: 30
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- DLL4, Notch signaling, vascular tumors, endothelial activation, drug safety, cancer treatment side effects, organ homeostasis, angiogenesis
- MeSH terms
- Animals, Antineoplastic Agents, Calcium-Binding Proteins, Humans, Macaca fascicularis, Membrane Proteins, Signal Transduction, Vascular Neoplasms, Endothelial Cells, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Mice, Rats, Receptors, Notch, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.